Long-Term PF-06651600 for the Treatment of Alopecia Areata (ALLEGRO-LT)
What is the purpose of this trial?
This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata. Eligible patients from the prior studies B7931005 (NCT02974868) and B7981015 (NCT03732807) will have an opportunity to enroll as well as patients who have not previously participated in either of these studies. The study is open-label and all patients entering the study will receive active study drug.
- Ages12 years and older
- Trial withPfizer Inc., U.S. Pharmaceuticals Group
- Start Date02/27/2020
- End Date04/30/2023
- Last Updated04/22/2020
- Study HIC#2000026562